L&K Biomed Ltd. announced that it expects to receive KRW 16.99996803 billion in funding from ValueSystem Investment Management Corp., Susung Asset Management Co., Ltd., W Asset Management Co., Ltd., Orion Capital Management
May 24, 2018
Share
L&K Biomed Ltd. (KOSDAQ:A156100) announced a private placement of series sixth unregistered coupon unguaranteed private convertible debentures for KRW 6,000,000,000 and 1,259,298 shares at a price of KRW 8,735 per share for KRW 10,999,968,030 for total gross proceeds of KRW 16,999,968,030. The transaction will include participation from Investments dealer concerned of Fund 1, a fund managed by Susung Asset Management Co., Ltd., Investments dealer concerned of Fund 2, a fund managed by Susung Asset Management Co., Ltd., Investments dealer concerned of Fund 7, a fund managed by Orion Capital Management for 1,000,000,000 each respectively, and other investors. The shares have a lock-up period of 1 year. The bonds do not have any interest rate. The bonds are issued at par and would mature on June 1, 2023. The bonds are 100% convertible into 603,015 common shares at a price of KRW 9,950 per share. The conversion period is from June 1, 2019 to May 1, 2023. The subscription and payment date is on June 1, 2018. The transaction has been approved by the board of directors of the company.
L&K BIOMED CO., LTD. is a Korea-based company mainly engaged in the research, development and manufacture of medical devices. The Companyâs products consist of medical devices and medical equipment. Its medical devices include cervical spine products, such as cervical plate systems, cervical screw systems and cervical cage system, as well as thoracolumbar spine products and others. Its medical equipment includes three dimensional (3D) full-body scanners. It also engages in the bio-similar business, which develops cell engineering.
L&K Biomed Ltd. announced that it expects to receive KRW 16.99996803 billion in funding from ValueSystem Investment Management Corp., Susung Asset Management Co., Ltd., W Asset Management Co., Ltd., Orion Capital Management